Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mimi Hu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bioresource Technology|October 20, 2025
Engineering strategies and tolerance mechanisms for robust d-lactate producer development of Zymomonas mobilisMimi Hu, Yunhao Chen, Binan Geng, et al.
Biotechnology for Biofuels|December 5, 2021
Development and characterization of efficient xylose utilization strains of Zymomonas mobilisJiyun Lou, Jingwen Wang, Yongfu Yang, et al.
Frontiers in Bioengineering and Biotechnology|March 10, 2023
Metabolic engineering of <i>Zymomonas mobilis</i> for co-production of D-lactic acid and ethanol using waste feedstocks of molasses and corncob residue hydrolysateMimi Hu, Weiwei Bao, Qiqun Peng, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Vitamin D deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patientsRakhshandra Talpur, Katherine M Cox, Mimi Hu, et al.
Microbial Cell Factories|October 5, 2019
Establishment and application of a CRISPR-Cas12a assisted genome-editing system in Zymomonas mobilisWei Shen, Jun Zhang, Binan Geng, et al.
NPJ Precision Oncology|March 4, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, et al.
The Journal of Clinical Endocrinology and Metabolism|November 28, 2012
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoringAubrey A Carhill, Maria E Cabanillas, Camilo Jimenez, et al.
Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.
Surgery|October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinomaJessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bioresource Technology|October 20, 2025
Engineering strategies and tolerance mechanisms for robust d-lactate producer development of Zymomonas mobilisMimi Hu, Yunhao Chen, Binan Geng, et al.
Biotechnology for Biofuels|December 5, 2021
Development and characterization of efficient xylose utilization strains of Zymomonas mobilisJiyun Lou, Jingwen Wang, Yongfu Yang, et al.
Frontiers in Bioengineering and Biotechnology|March 10, 2023
Metabolic engineering of <i>Zymomonas mobilis</i> for co-production of D-lactic acid and ethanol using waste feedstocks of molasses and corncob residue hydrolysateMimi Hu, Weiwei Bao, Qiqun Peng, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Vitamin D deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patientsRakhshandra Talpur, Katherine M Cox, Mimi Hu, et al.
Microbial Cell Factories|October 5, 2019
Establishment and application of a CRISPR-Cas12a assisted genome-editing system in Zymomonas mobilisWei Shen, Jun Zhang, Binan Geng, et al.
NPJ Precision Oncology|March 4, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, et al.
The Journal of Clinical Endocrinology and Metabolism|November 28, 2012
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoringAubrey A Carhill, Maria E Cabanillas, Camilo Jimenez, et al.
Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.
Surgery|October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinomaJessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Pageof 3